Compare JPMorgan Chase & Co (JPM) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Chase & Co vs TransMedics Group Inc — how do they compare? JPMorgan Chase & Co trades at $365.48 (market cap $962.37B), while TransMedics Group Inc trades at $87.08 (market cap $3.10B). The key difference: JPMorgan Chase & Co is far larger — about 310.4× TransMedics Group Inc's market cap, and JPMorgan Chase & Co pays a 1.66% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| JPM | TMDX | |
|---|---|---|
Market Cap | $962.37B | $3.10B |
Volume | 10,479,943 | — |
Sector | Financials | Technology |
52-Week High | $362.04 | $150.42 |
52-Week Low | $282.84 | $61.99 |
Dividend Yield | 1.66% | — |
Enterprise Value | — | $3.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JPMorgan Chase & Co. (JPM) trades at $365.63, up 1.62% today, with a bullish technical outlook and strong fundamentals. Recent earnings beat expectations in Q1 and Q2 2026, with revenue growth from $181.85B in 2025 to an estimated $194.9B in 2026. The stock shows robust profitability with a net income margin of 33.38% and ROE of 18.43%, supported by a moderate P/E of 15.51. Analyst consensus is a 'Moderate Buy' with a $374.18 price target, indicating potential upside amid positive sentiment.
JPM offers a solid investment case driven by earnings growth and sector leadership, but faces risks from macroeconomic volatility and geopolitical tensions. The stock's current price near resistance at $366 requires monitoring for breakout potential, while institutional accumulation and CEO insights on economic risks highlight both opportunity and caution for investors.
TransMedics Group (TMDX) trades at $87.42, down 1.12% on the day, with a bullish technical outlook from moving averages but bearish oscillators signaling potential overbought conditions. The company reported mixed Q2 2026 results, missing earnings estimates with EPS of $0.44 versus $0.50 expected, while revenue growth remains robust. Recent news highlights an ongoing investigation into fiduciary duties by directors, adding uncertainty.
The stock presents a cautious opportunity with strong analyst support (69% buy ratings) and a consensus price target of $99.57, implying upside, but risks include earnings volatility, margin pressures, and legal scrutiny. Fundamentals show solid profitability with a 22.69% net margin, though valuation multiples like P/E of 23.15 suggest premium pricing relative to historical norms.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
